SS
CADL icon

SBI Securities’s Candel Therapeutics CADL Stock Holding History

SBI Securities’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$824 Buy
80
+60
+300% +$453 ﹤0.01% 2873
2026
Q1 		$98 Hold
20
– – ﹤0.01% 3412
2025
Q4 		$113 Sell
20
-1
-5% -$5 ﹤0.01% 3369
2025
Q3 		$107 Buy
21
+1
+5% +$6 ﹤0.01% 3494
2025
Q2 		$101 Buy
20
+10
+100% +$51 ﹤0.01% 3536
2025
Q1 		$57 Hold
10
– – ﹤0.01% 3606
2024
Q4 		$87 Buy
+10
New +$59 ﹤0.01% 3496

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SBI Securities's CADL Position: Q2 2026 in Review

SBI Securities increased its Candel Therapeutics (CADL) stake by 300% in Q2 2026, buying an estimated $453 and bringing the position to 80 shares worth $824. The position accounts for ﹤0.01% of the portfolio, ranked #2873.

SBI Securities first reported a position in CADL in Q4 2024 and has held it in 7 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • SBI Securities held 80 shares of Candel Therapeutics worth $824 as of Q2 2026.
  • SBI Securities bought 60 Candel Therapeutics shares in Q2 2026, an estimated $453.
  • Candel Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2873 holding.
  • SBI Securities first reported a position in Candel Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.